myNEO Therapeutics
Bruno Fant has a strong background in molecular biology and genetics with experience as a postdoctoral scientist in neuroscience. With a Master's degree in Complex Systems and Biologie moléculaire, Bruno has worked as a bioinformatician and large dataset molecular biology consultant. Currently serving as the Chief Technology Officer at myNEO Therapeutics, Bruno is leading the development of breakthrough immunotherapies to combat cancer by targeting novel tumor targets found in the dark genome.
This person is not in any teams
myNEO Therapeutics
myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond. In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response.